BioCentury
ARTICLE | Company News

AlphaVax, Novartis deal

January 5, 2009 8:00 AM UTC

AlphaVax granted Novartis exclusive, worldwide rights to develop and commercialize CMV alphavaccine ( AVX601) to prevent cytomegalovirus (CMV) infection. AlphaVax will receive $20 million up front an...